Related Experiment Video

Updated: May 1, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Setting the bar for therapeutic trials in non-small-cell lung cancer: how low can we go?

David H Johnson1

  • 1University of Texas Southwestern School of Medicine, Dallas, TX.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|April 2, 2014
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

6.0K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.2K

Related Experiment Videos

Last Updated: May 1, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

6.0K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K

Articles linked to this work by shared authors, journal, and citation graph.

Membrane Phase, Charge, and Curvature Regulate α-Synuclein Binding Dynamics.

Langmuir : the ACS journal of surfaces and colloids·2026

Membrane Remodeling by α-Synuclein Emerges from Complementary Contributions of Its Structured and Disordered Domains.

The journal of physical chemistry. B·2026

Cholesterol differentially regulates α-synuclein binding across membrane packing regimes.

Biophysical reports·2026

Morphological assessment of the Common Barn Owl Tyto alba (Strigiformes: Tytonidae) supports three species.

Zootaxa·2026

Cholesterol differentially regulates α-synuclein binding across membrane packing regimes.

bioRxiv : the preprint server for biology·2026

The moderating role of anxiety sensitivity in the association between momentary PTSD symptoms and suicide cognitions.

Behaviour research and therapy·2026

First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

When Survival Separates.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Transcriptomic Plasticity and Its Spatial Architecture Shape Melanoma Response to Immunotherapy and Its Combination With BRAF/MEKi.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Patient-Level Evaluation of Optimal Margin Width for Lumpectomy in Ductal Carcinoma In Situ: An Analysis of Patients in the National Cancer Database Special Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us